FDA Chief Scott Gottlieb issued an announcement about the agency’s continued efforts to encourage the adoption of medication-assisted treatment (MAT) for opioid addiction. MAT includes opioids such as methadone or buprenorphine, which can interact with benzodiazepines with deadly consequences. In an advisory last year, the FDA said more investigation about the extent of that danger was needed. Now, the agency says to proceed with caution. The statement reads in part: “As a result of that consideration, the FDA’s new advisory that we’re issuing today asks health care providers and patients to be aware of these risks. But at the same time, the agency is also reinforcing that MAT should not necessarily be denied to patients taking these other medications. The dangers associated with failing to treat an opioid use disorder can outweigh the risks of co-prescribing MAT and benzodiazepines.”
Read the full announcement here.